12:00 AM
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Lytixar: Phase IIa start

This half, Lytix will begin a double-blind, placebo-controlled, Hungarian Phase IIa trial to evaluate 1, 2 and 5%...

Read the full 68 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >